Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | KCNN2 | Q9H2S1 | 4/20 | 0.47 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369716 | 0.82 | MAOA (0.63) | MAOADHFRSMN1; SMN2CA7KMT2A | |
| SCHEMBL28239143 | 0.81 | DRD1 (0.50) | KMT2ADRD2DRD1DRD3SIGMAR1 | |
| SCHEMBL22782327 | 0.79 | MAOA (0.67) | MAOADHFRSMN1; SMN2CA7KCNN2 | |
| SCHEMBL5289084 | 0.77 | SMN1; SMN2 (0.61) | MAOADHFRSMN1; SMN2CA7KMT2A | |
| SCHEMBL28742794 | 0.76 | DRD2 (0.56) | MAOADHFRDRD2DRD1DRD3 | |
| SCHEMBL23395314 | 0.75 | ESR1 (0.48) | DRD2DRD1DRD3 | |
| SCHEMBL22970640 | 0.75 | CA7 (0.57) | MAOADHFRSMN1; SMN2CA7KMT2A | |
| SCHEMBL27736180 | 0.75 | DRD2 (0.60) | MAOADHFRSMN1; SMN2CA7KMT2A | |
| SCHEMBL1760713 | 0.74 | MAOA (0.97) | MAOASMN1; SMN2CA7KCNN2KCNN3 | |
| SCHEMBL19888927 | 0.74 | MAOA (0.97) | MAOASMN1; SMN2CA7KCNN2KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040066-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040066-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | PDE4B, PDE7B, PDE4A | MAOA 1442/4885DHFR 163/4885SMN1; SMN2 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.